跳至主要内容
临床试验/JPRN-UMIN000031459
JPRN-UMIN000031459已完成2 期

Phase II study of safety and efficacy of alternating R-CHOP and R-HDMA therapy in high-risk diffuse large B-cell lymphoma - Safety and efficacy of alternating R-CHOP and R-HDMA therapy in high-risk DLBC

Division of Hematology, Keio University School of Medicine0 个研究点目标入组 5 人开始时间: 2018年3月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1 Involvement of central nervous system 2 HBs antigen positive 3 HCV antibody positive 4 HIV antibody positive 5 Active synchronous malignancy 6 Patients who are pregnant, lactating, or possibly pregnant 7 Patients who receive steroid therapy for other diseases 8 Patients with uncontrolled infection 9 Severe allergy to drugs used in this study 10Patients who the researcher judged inappropriate as the subject

研究者

发起方
Division of Hematology, Keio University School of Medicine

相似试验

Phase II study of safety and efficacy of ... | 临床试验